GlobeStar Therapeutics Co. (OTCMKTS:GSTC) Sees Large Drop in Short Interest

GlobeStar Therapeutics Co. (OTCMKTS:GSTCGet Free Report) was the recipient of a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 3,200 shares, a decline of 91.0% from the January 31st total of 35,600 shares. Based on an average trading volume of 10,934,400 shares, the short-interest ratio is presently 0.0 days.

GlobeStar Therapeutics Price Performance

OTCMKTS GSTC traded up $0.00 on Friday, reaching $0.00. The company’s stock had a trading volume of 24,644 shares, compared to its average volume of 4,093,095. GlobeStar Therapeutics has a twelve month low of $0.00 and a twelve month high of $0.00.

GlobeStar Therapeutics Company Profile

(Get Free Report)

GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. It offers Amethyst, a compound intended to treat neurodegeneration. The company was formerly known as AngioSoma, Inc and changed its name to GlobeStar Therapeutics Corporation in July 2021.

Featured Stories

Receive News & Ratings for GlobeStar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlobeStar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.